FDA approves GW’s Epidiolex, first marijuana-derived drug

FDA approved Epidiolex cannabidiol from GW Pharmaceuticals plc (NASDAQ:GWPH) on June 25, marking the first U.S. approval of a marijuana-derived purified substance, according to the agency. Epidiolex is indicated to treat seizures associated with Lennox-Gastaut

Read the full 359 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE